Lv3
380 积分 2025-03-14 加入
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
8天前
已完结
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
8天前
已完结
Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
10天前
已关闭
PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease
10天前
已完结
Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study
10天前
已关闭
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era
10天前
已完结
BAFF-R, the major B cell–activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders
11天前
已完结
BAFF receptor antibody for mantle cell lymphoma therapy
13天前
已完结
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma
18天前
已完结
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
22天前
已完结
皖公网安备34019202002308
